Acute Leukemia Endpoints Meeting Information
The U.S. Food and Drug Administration (FDA) is holding a public workshop on clinical endpoints in acute leukemia. The workshop will discuss clinical trial endpoints that have not been generally accepted but have potential utility for the measurement of clinical benefit or the prediction of clinical benefit with reasonable likelihood for the following disease entities:
Pediatric Acute Lymphocytic Leukemia
Adult Acute Lymphocytic Leukemia
Pediatric Acute Myeloid Leukemia
Adult Acute Myeloid Leukemia
Acute Leukemia in the Elderly
Issues identified in the workshops will be further discussed before the Oncologic Drugs Advisory Committee (ODAC) and thereafter will be detailed in FDA Guidance Documents.
Date: June 24, 2005, from 8:30 a.m. – 5:00 p.m.
Address: JW Marriott Hotel Pennsylvania Avenue
Salons F and E
1331 Pennsylvania Avenue, NW
Washington, DC 20004
Registration: To register for the workshop, please visit the ASH Web site
For further information, contact:
The American Society of Hematology (ASH) Government Affairs and Practice Coordinator Stephanie Kart at email@example.com or (202) 776-0544.